Cue Biopharma (CUE) Price to Sales (2018 - 2026)

Cue Biopharma has disclosed Price to Sales across 9 years of filings, most recently posting 20.95 for Q2 2026.

• In Q2 2026, Price to Sales fell 96.04% year-over-year to 20.95; the TTM figure through Jun 2026 stood at 7.34 (down 96.11% YoY), while the FY2025 annual figure was 32.19, down 85.21% from the prior year.
• Price to Sales came in at 20.95 for Q2 2026 at Cue Biopharma, down from 93.06 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 101654.47 in Q2 2022 to a low of 20.95 in Q2 2026.
• Average Price to Sales over 5 years is 11943.32, with a median of 1606.33 recorded in 2024.
• Year-over-year, Price to Sales surged 2431.46% in 2022 and sank 96.59% in 2023.
• Over 5 years, Price to Sales stood at 20185.44 in 2022, then tumbled by 89.83% to 2053.51 in 2023, then sank by 37.54% to 1282.67 in 2024, then sank by 92.74% to 93.06 in 2025, then tumbled by 77.49% to 20.95 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 20.95 in Q2 2026, 93.06 in Q4 2025, and 1012.45 in Q3 2025.